This document summarizes NuLiv Science International's research and business operations, which are built around 6 interconnected platforms: research on metabolism, discovery of bioactive botanical fractions and compounds, production process development, supplement product development, sourcing and quality control of botanical ingredients, and a futuristic wellness products platform. NuLiv focuses its research on Traditional Chinese Medicine herbs and their effects on metabolic pathways, with the goal of discovering novel bioactive compounds. It operates laboratories in Taipei and Shanghai and has partnerships with academic institutions for research support.
The document summarizes NuLiv Science International's research focused on metabolism and the discovery of bioactive botanical fractions and compounds. It describes NuLiv's 6 interconnected business platforms, including focused research on metabolism, discovery of bioactive fractions/compounds, development of production processes, supplement products, sourcing/QC, and future wellness products. It provides details on NuLiv's research facilities, management team, scientific advisors, in vitro/in vivo/human research platforms, patents, and published papers. It also summarizes 6 bioactive fractions/compounds discovered and proprietary nutraceutical ingredients formulated with them.
This document summarizes the key differences between in vitro and in vivo experiments. In vitro refers to experiments performed outside of a living organism in artificial laboratory conditions, such as cell cultures or test tubes. In vivo experiments are conducted within living organisms under natural physiological conditions. Some key differences highlighted are that in vitro experiments are less expensive and faster but also less precise, while in vivo can provide more accurate results but are more time-consuming and costly. Examples of each type of experiment are also provided.
This document provides information on conducting safety pharmacology and toxicology studies for pharmaceuticals. It describes various in vivo and in vitro models used to study the effects of drugs on the central nervous, cardiovascular and respiratory systems as well as metabolism and various disease models. It also outlines general toxicology, genotoxicity, reproductive toxicity and immunotoxicity studies. Both animal and cellular assays are discussed for evaluating potential adverse effects of drug candidates.
The International Conference on Harmonization (ICH) aims to harmonize technical requirements for pharmaceutical registration internationally. ICH involves regulators and industry from the EU, Japan, and US. Its objectives are to ensure safe, effective, and high-quality medicines are developed efficiently through international agreement on guidelines. ICH has produced guidelines addressing safety issues like carcinogenicity and QT prolongation. Proposed changes to rodent carcinogenicity testing aim to introduce a more comprehensive risk assessment approach.
This study evaluated the antiasthmatic potential of a polyherbal formulation containing extracts of four plants - Solanum xanthocarpum, Aegle marmelos, Caesalpinia bonduc, and Murraya koenigii. Experimental models in rats and guinea pigs were used to assess mast cell stabilization, antihistaminic, and anticholinergic effects. The results demonstrated that the polyherbal formulation dose-dependently inhibited mast cell degranulation and protected against histamine- and acetylcholine-induced bronchospasm in guinea pigs, suggesting antiasthmatic effects through mast cell membrane stabilization, antihistaminic, and anticholinergic mechanisms of action. This
Non animal technology the future is amazing, and animal-free. #vivisection ...All Animal Rights
This document discusses several non-animal technologies that can be used instead of animal testing for medical research and product safety testing, including computer modeling, cell culture, microdosing, proteomics, and various brain imaging technologies. It provides examples of each technique and how they are being used and developed as alternatives to animal testing, which is described as being less accurate and predictive than these human-relevant methods. The document advocates for increased adoption of these non-animal technologies to advance medical research and testing in a human-centered manner.
This document provides ethical guidelines for the care and use of animals in health research in Nepal. It was created by the Nepal Health Research Council to ensure animals are treated humanely and research follows international standards. The guidelines cover responsible conduct of research, housing and care of animals, acquiring and transporting animals, research procedures, field research, educational use of animals, record keeping, and oversight by an ethical review board. The goal is to promote the welfare of animals used in research while advancing scientific knowledge.
The document summarizes NuLiv Science International's research focused on metabolism and the discovery of bioactive botanical fractions and compounds. It describes NuLiv's 6 interconnected business platforms, including focused research on metabolism, discovery of bioactive fractions/compounds, development of production processes, supplement products, sourcing/QC, and future wellness products. It provides details on NuLiv's research facilities, management team, scientific advisors, in vitro/in vivo/human research platforms, patents, and published papers. It also summarizes 6 bioactive fractions/compounds discovered and proprietary nutraceutical ingredients formulated with them.
This document summarizes the key differences between in vitro and in vivo experiments. In vitro refers to experiments performed outside of a living organism in artificial laboratory conditions, such as cell cultures or test tubes. In vivo experiments are conducted within living organisms under natural physiological conditions. Some key differences highlighted are that in vitro experiments are less expensive and faster but also less precise, while in vivo can provide more accurate results but are more time-consuming and costly. Examples of each type of experiment are also provided.
This document provides information on conducting safety pharmacology and toxicology studies for pharmaceuticals. It describes various in vivo and in vitro models used to study the effects of drugs on the central nervous, cardiovascular and respiratory systems as well as metabolism and various disease models. It also outlines general toxicology, genotoxicity, reproductive toxicity and immunotoxicity studies. Both animal and cellular assays are discussed for evaluating potential adverse effects of drug candidates.
The International Conference on Harmonization (ICH) aims to harmonize technical requirements for pharmaceutical registration internationally. ICH involves regulators and industry from the EU, Japan, and US. Its objectives are to ensure safe, effective, and high-quality medicines are developed efficiently through international agreement on guidelines. ICH has produced guidelines addressing safety issues like carcinogenicity and QT prolongation. Proposed changes to rodent carcinogenicity testing aim to introduce a more comprehensive risk assessment approach.
This study evaluated the antiasthmatic potential of a polyherbal formulation containing extracts of four plants - Solanum xanthocarpum, Aegle marmelos, Caesalpinia bonduc, and Murraya koenigii. Experimental models in rats and guinea pigs were used to assess mast cell stabilization, antihistaminic, and anticholinergic effects. The results demonstrated that the polyherbal formulation dose-dependently inhibited mast cell degranulation and protected against histamine- and acetylcholine-induced bronchospasm in guinea pigs, suggesting antiasthmatic effects through mast cell membrane stabilization, antihistaminic, and anticholinergic mechanisms of action. This
Non animal technology the future is amazing, and animal-free. #vivisection ...All Animal Rights
This document discusses several non-animal technologies that can be used instead of animal testing for medical research and product safety testing, including computer modeling, cell culture, microdosing, proteomics, and various brain imaging technologies. It provides examples of each technique and how they are being used and developed as alternatives to animal testing, which is described as being less accurate and predictive than these human-relevant methods. The document advocates for increased adoption of these non-animal technologies to advance medical research and testing in a human-centered manner.
This document provides ethical guidelines for the care and use of animals in health research in Nepal. It was created by the Nepal Health Research Council to ensure animals are treated humanely and research follows international standards. The guidelines cover responsible conduct of research, housing and care of animals, acquiring and transporting animals, research procedures, field research, educational use of animals, record keeping, and oversight by an ethical review board. The goal is to promote the welfare of animals used in research while advancing scientific knowledge.
Assignment on Alternatives to Animal Screening MethodDeepak Kumar
Toxicity studies are generally performed to determine drug effects that cannot be evaluated through standard pharmacology profiles or that only occur with repeated administration. Most toxicity tests are performed in two species, such as a rodent and non-rodent, to avoid overlooking unexpected adverse effects before introducing new chemical entities into humans. While animal testing has faced controversy, alternatives using biotechnology tools such as transgenic animal models, cell cultures, and in silico methods are being developed wherever possible to reduce animal use. These alternative techniques include cell line techniques, full thickness skin models, and patch clamp methods to study ion channels at a cellular level.
Hepatoprotective Effect of Cestrum parqui L. aerial parts and Phytochemical ...Jing Zang
This study deals with the investigation of hepatoprotective effect of 70% methanolic extract from Cestrum parqui aerial parts and determination of the bioactive components of the plant. The hepatoprotective effect of Cestrum parqui methanol extract (100, 500, 1000 mg/kg) was analysed on carbon tetrachloride (CCl4)-induced acute liver injury. The administration of a single dose of 40% CCl4 (1ml/kg b.w.) causes an increase in the activities of serum alanine aminotransferase (ALT) and aspirate aminotransferase (AST) enzymes and so pretreated orally of a dose from Cestrum parqui methanol extract (100, 500, 1000 mg/kg) and silymarin (200 mg/kg) for three consecutive days prior to The administration of a single dose of CCl4 significantly prevented the increase in the activities of these enzymes. Histological analysis showed that Cestrum parqui methanol extract at doses of 500 and 1000 mg/kg and silymarin reduced the incidence of liver lesions including vacuole formation, neutrophil infiltration and necrosis of hepatocytes induced by CCl4. The extract cause a negative result on the antioxidative enzymes, superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GRd) and decreased malondialdehyde (MDA) level in liver, as compared to those in the CCl4-treated group and this suggests that the hepatoprotective activity of the extract is due to the antioxidant effect of the extract. Phytochemical analysis of the methanol extract from Cestrum parqui aerial parts showed that it contained different phytoconstituents, flavonoids, tannins, saponins, alkaloids, terpenes and carbohydrates.
This document discusses in-vivo methods for determining drug permeability and absorption. It describes two main types of in-vivo methods: direct and indirect. The direct method involves measuring drug levels in blood or urine over time after administration to determine the rate and extent of absorption. The indirect method measures pharmacological response instead of drug concentration when direct measurement is difficult. In-vivo methods provide a more precise understanding of factors like gastric emptying and drug effects on the gastrointestinal tract compared to in-vitro or in situ methods.
This document provides a bio-data or curriculum vitae for Prof. Yamini Bhusan Tripathi. It lists his personal details including name, date of birth, education, positions held, research experience, publications, projects, awards, patents, books, and training. It shows that he is a professor of medicinal chemistry with over 36 years of teaching and research experience, having published over 129 papers and authored or edited several books and book chapters in his field.
This document provides guidelines for safety pharmacology and toxicology studies for pharmaceutical products. It outlines the objectives and types of studies recommended at different stages of clinical development, including safety pharmacology core battery studies, follow-up studies, reproductive and developmental toxicity studies, and human studies. Test systems, dose levels, durations, endpoints, and good laboratory practice standards are discussed for each type of nonclinical study.
The document discusses alternative techniques to animal testing in drug and chemical research. It defines alternatives as methods that replace, reduce, or refine animal use. Several specific alternative techniques are described, including full thickness skin models, in silico computer modeling, cell line techniques, and patch clamp electrophysiology. The techniques aim to provide comparable data to animal tests while avoiding or minimizing animal use.
The document discusses the importance of good laboratory practice (GLP) in ensuring quality and validity of test data. It outlines key aspects of GLP including its history, objectives to promote international acceptance and integrity of data. GLP provides a framework for planning, performing, monitoring and reporting laboratory activities according to regulations. Adhering to GLP guidelines and standards for personnel, equipment management, safety and turnaround time helps produce reliable and reproducible results.
Ethical issues in animal experimentation (with emphasis on CPCSEA guidelines)Sandeep Lahiry
The document discusses ethical issues related to animal experimentation, summarizing Indian and international guidelines. It outlines the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) which regulates animal testing in India according to the Prevention of Cruelty to Animals Act. The CPCSEA guidelines emphasize minimizing animal use, pain and suffering, and proper housing and care. Institutional Animal Ethics Committees must approve all research projects involving animals.
This document discusses safety pharmacology studies, with a focus on respiratory and central nervous system safety pharmacology. It defines safety pharmacology studies as investigating potential undesirable pharmacological effects of substances on physiological functions. For respiratory safety pharmacology, the core battery studies measure respiratory rate, tidal volume, and oxygen saturation. Supplementary studies measure airway resistance and lung compliance. For CNS safety pharmacology, core studies evaluate behavior, locomotor activity, motor coordination, and seizure liability. Safety pharmacology aims to identify risks and inform safe starting doses in clinical trials.
Alternatives to animal screening methods p'screening. mohammadhusainVasaya Mohammadhusain
1) The document presents information on alternatives to animal testing for toxicity screening such as biotechnology methods like cell cultures and transgenic animal models.
2) In vitro methods like cell lines and tissue cultures can be used to test substances and reduce animal numbers. Full thickness skin models and in silico modeling are also described.
3) Techniques like the patch clamp method allow studying ion channels in isolated cells like kidney cells to understand transport processes without whole animal experiments.
Assessing oral drug absorption and metabolism in human intestinal tissuesBiopta Inc.
Presentation from "Addressing Biological Barriers" Conference organised by Molecular Profiles on 22 Jan 2014 in Nottingham, UK. Fresh functional human tissues are increasingly recognised as an effective way to model oral drug absorption and metabolism; Biopta is a contract research organisation that offers services in DMPK.
This document provides a biography and resume for Dr. Rahul A. Hajare, a researcher in biologics development and protein chemistry. It summarizes his educational background, areas of research interest, research experience, awards, publications, projects, and academic appointments. Some key details include that he received a Ph.D. in 2012 from Vinayaka Mission University and has over 52 publications. His research focuses on areas like biologics development, protein chemistry, molecular biology, and drug discovery. He has worked on projects related to HIV inhibition and anticancer activity.
This research article summarizes a study encapsulating curcumin, a natural anti-cancer compound, in polymeric micelles for cancer therapy. The researchers synthesized a diblock copolymer micelle (PNPC) from methoxy polyethylene glycol and oleic acid to encapsulate curcumin. They showed that PNPC had high drug loading efficiency and stability. In vitro, PNPC significantly suppressed the proliferation of breast and liver cancer cell lines. In an animal model of breast cancer, PNPC treatment reduced tumor incidence and size compared to controls. PNPC also increased expression of pro-apoptotic genes and decreased expression of anti-apoptotic and proliferative genes in the tumors. The results suggest PNPC is a
OECD Guidline on acute and chronic toxicityShital Magar
This document provides an overview of toxicology and various guidelines for assessing acute and chronic toxicity of substances, including LD50, LC50, and OECD test guidelines. It discusses the principles of acute oral toxicity testing, limitations of LD50 values, more humane OECD guidelines, and alternatives to animal testing. The guidelines described include those for acute oral toxicity (401, 420, 423, 425), carcinogenicity (451), and chronic toxicity (452).
General toxicology testing refers to a series of toxicity tests required by international regulators to prove safety in experimental animals prior to human testing. It includes acute, sub-acute, and chronic toxicity tests conducted according to OECD guidelines in rodents and non-rodents. Preclinical studies include phytochemistry, formulation development, pharmacology/pharmacokinetic profiling, safety toxicology studies, and efficacy studies. Toxicology studies are guided by regulatory requirements like OECD/ICH guidelines and Good Laboratory Practices to ensure quality. Acute, sub-acute, and chronic toxicity tests provide information on toxicity effects from single or repeated substance exposure over different time periods and help determine safe doses for clinical trials.
This document describes Barktastic natural apple berry treats for dogs. The treats contain concentrated fruit purees from apples and berries, as well as omega-3 and vitamin C. They are grain free and contain only natural ingredients like purified fish oil, calcium, and apple fiber powder. Nutrition facts are provided, listing the treats as low in calories, fat, and sugars, with fiber as the leading carbohydrate. The treats are presented as 100% natural, containing whole apples, and suitable for both training and occasional supplemental use.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise boosts blood flow, releases endorphins, and promotes changes in the brain which help enhance one's emotional well-being and mental clarity.
Fruit Snack Co. is opening a new fruit snack production facility in the vacant former CanGro Foods Inc. plant in St. Davids, Ontario. The facility will initially employ 9 people and process local fruits like peaches and pears into healthy, natural fruit snacks. The startup received $884,570 in funding from the province and will provide new markets for local fruit growers to sell bruised or damaged crops. The owner, John Boot, has over 20 years of experience in the dried fruit snack industry and previously founded and sold another successful fruit snack company in British Columbia.
Fruit Snack Co. is opening a new fruit snack production facility in the vacant former CanGro Foods Inc. plant in St. Davids, Ontario. The facility will initially employ 9 people and process local fruits like peaches and pears into healthy, natural fruit snacks. The startup received $884,570 in funding from the province and will provide new markets for local fruit growers to sell bruised or damaged crops. The owner, John Boot, has over 20 years of experience in the dried fruit snack industry and hopes to create a similar successful operation in Niagara to process local fruits into snacks.
This document is a nutrition label and packaging for Barktastic Fruit Treats, a natural dog treat made from apple and berries. The treats are intended to be healthy training rewards for dogs, containing vitamin C, omega-3 fatty acids, and no artificial flavors, colors, preservatives or added sugars. The story of Rosie, a shy puppy who was inspired to create the treats, is described on the packaging. Feeding guidelines recommend the treats as a supplemental snack equivalent to half an apple.
Fortis Clinical Research Ltd. is a leading clinical research organization in India that provides various clinical research services to support the global pharmaceutical industry in drug development. The document outlines Fortis' vision, services, leadership team, facilities, capabilities, and experience conducting various types of clinical trials and bioanalytical work.
Assignment on Alternatives to Animal Screening MethodDeepak Kumar
Toxicity studies are generally performed to determine drug effects that cannot be evaluated through standard pharmacology profiles or that only occur with repeated administration. Most toxicity tests are performed in two species, such as a rodent and non-rodent, to avoid overlooking unexpected adverse effects before introducing new chemical entities into humans. While animal testing has faced controversy, alternatives using biotechnology tools such as transgenic animal models, cell cultures, and in silico methods are being developed wherever possible to reduce animal use. These alternative techniques include cell line techniques, full thickness skin models, and patch clamp methods to study ion channels at a cellular level.
Hepatoprotective Effect of Cestrum parqui L. aerial parts and Phytochemical ...Jing Zang
This study deals with the investigation of hepatoprotective effect of 70% methanolic extract from Cestrum parqui aerial parts and determination of the bioactive components of the plant. The hepatoprotective effect of Cestrum parqui methanol extract (100, 500, 1000 mg/kg) was analysed on carbon tetrachloride (CCl4)-induced acute liver injury. The administration of a single dose of 40% CCl4 (1ml/kg b.w.) causes an increase in the activities of serum alanine aminotransferase (ALT) and aspirate aminotransferase (AST) enzymes and so pretreated orally of a dose from Cestrum parqui methanol extract (100, 500, 1000 mg/kg) and silymarin (200 mg/kg) for three consecutive days prior to The administration of a single dose of CCl4 significantly prevented the increase in the activities of these enzymes. Histological analysis showed that Cestrum parqui methanol extract at doses of 500 and 1000 mg/kg and silymarin reduced the incidence of liver lesions including vacuole formation, neutrophil infiltration and necrosis of hepatocytes induced by CCl4. The extract cause a negative result on the antioxidative enzymes, superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GRd) and decreased malondialdehyde (MDA) level in liver, as compared to those in the CCl4-treated group and this suggests that the hepatoprotective activity of the extract is due to the antioxidant effect of the extract. Phytochemical analysis of the methanol extract from Cestrum parqui aerial parts showed that it contained different phytoconstituents, flavonoids, tannins, saponins, alkaloids, terpenes and carbohydrates.
This document discusses in-vivo methods for determining drug permeability and absorption. It describes two main types of in-vivo methods: direct and indirect. The direct method involves measuring drug levels in blood or urine over time after administration to determine the rate and extent of absorption. The indirect method measures pharmacological response instead of drug concentration when direct measurement is difficult. In-vivo methods provide a more precise understanding of factors like gastric emptying and drug effects on the gastrointestinal tract compared to in-vitro or in situ methods.
This document provides a bio-data or curriculum vitae for Prof. Yamini Bhusan Tripathi. It lists his personal details including name, date of birth, education, positions held, research experience, publications, projects, awards, patents, books, and training. It shows that he is a professor of medicinal chemistry with over 36 years of teaching and research experience, having published over 129 papers and authored or edited several books and book chapters in his field.
This document provides guidelines for safety pharmacology and toxicology studies for pharmaceutical products. It outlines the objectives and types of studies recommended at different stages of clinical development, including safety pharmacology core battery studies, follow-up studies, reproductive and developmental toxicity studies, and human studies. Test systems, dose levels, durations, endpoints, and good laboratory practice standards are discussed for each type of nonclinical study.
The document discusses alternative techniques to animal testing in drug and chemical research. It defines alternatives as methods that replace, reduce, or refine animal use. Several specific alternative techniques are described, including full thickness skin models, in silico computer modeling, cell line techniques, and patch clamp electrophysiology. The techniques aim to provide comparable data to animal tests while avoiding or minimizing animal use.
The document discusses the importance of good laboratory practice (GLP) in ensuring quality and validity of test data. It outlines key aspects of GLP including its history, objectives to promote international acceptance and integrity of data. GLP provides a framework for planning, performing, monitoring and reporting laboratory activities according to regulations. Adhering to GLP guidelines and standards for personnel, equipment management, safety and turnaround time helps produce reliable and reproducible results.
Ethical issues in animal experimentation (with emphasis on CPCSEA guidelines)Sandeep Lahiry
The document discusses ethical issues related to animal experimentation, summarizing Indian and international guidelines. It outlines the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) which regulates animal testing in India according to the Prevention of Cruelty to Animals Act. The CPCSEA guidelines emphasize minimizing animal use, pain and suffering, and proper housing and care. Institutional Animal Ethics Committees must approve all research projects involving animals.
This document discusses safety pharmacology studies, with a focus on respiratory and central nervous system safety pharmacology. It defines safety pharmacology studies as investigating potential undesirable pharmacological effects of substances on physiological functions. For respiratory safety pharmacology, the core battery studies measure respiratory rate, tidal volume, and oxygen saturation. Supplementary studies measure airway resistance and lung compliance. For CNS safety pharmacology, core studies evaluate behavior, locomotor activity, motor coordination, and seizure liability. Safety pharmacology aims to identify risks and inform safe starting doses in clinical trials.
Alternatives to animal screening methods p'screening. mohammadhusainVasaya Mohammadhusain
1) The document presents information on alternatives to animal testing for toxicity screening such as biotechnology methods like cell cultures and transgenic animal models.
2) In vitro methods like cell lines and tissue cultures can be used to test substances and reduce animal numbers. Full thickness skin models and in silico modeling are also described.
3) Techniques like the patch clamp method allow studying ion channels in isolated cells like kidney cells to understand transport processes without whole animal experiments.
Assessing oral drug absorption and metabolism in human intestinal tissuesBiopta Inc.
Presentation from "Addressing Biological Barriers" Conference organised by Molecular Profiles on 22 Jan 2014 in Nottingham, UK. Fresh functional human tissues are increasingly recognised as an effective way to model oral drug absorption and metabolism; Biopta is a contract research organisation that offers services in DMPK.
This document provides a biography and resume for Dr. Rahul A. Hajare, a researcher in biologics development and protein chemistry. It summarizes his educational background, areas of research interest, research experience, awards, publications, projects, and academic appointments. Some key details include that he received a Ph.D. in 2012 from Vinayaka Mission University and has over 52 publications. His research focuses on areas like biologics development, protein chemistry, molecular biology, and drug discovery. He has worked on projects related to HIV inhibition and anticancer activity.
This research article summarizes a study encapsulating curcumin, a natural anti-cancer compound, in polymeric micelles for cancer therapy. The researchers synthesized a diblock copolymer micelle (PNPC) from methoxy polyethylene glycol and oleic acid to encapsulate curcumin. They showed that PNPC had high drug loading efficiency and stability. In vitro, PNPC significantly suppressed the proliferation of breast and liver cancer cell lines. In an animal model of breast cancer, PNPC treatment reduced tumor incidence and size compared to controls. PNPC also increased expression of pro-apoptotic genes and decreased expression of anti-apoptotic and proliferative genes in the tumors. The results suggest PNPC is a
OECD Guidline on acute and chronic toxicityShital Magar
This document provides an overview of toxicology and various guidelines for assessing acute and chronic toxicity of substances, including LD50, LC50, and OECD test guidelines. It discusses the principles of acute oral toxicity testing, limitations of LD50 values, more humane OECD guidelines, and alternatives to animal testing. The guidelines described include those for acute oral toxicity (401, 420, 423, 425), carcinogenicity (451), and chronic toxicity (452).
General toxicology testing refers to a series of toxicity tests required by international regulators to prove safety in experimental animals prior to human testing. It includes acute, sub-acute, and chronic toxicity tests conducted according to OECD guidelines in rodents and non-rodents. Preclinical studies include phytochemistry, formulation development, pharmacology/pharmacokinetic profiling, safety toxicology studies, and efficacy studies. Toxicology studies are guided by regulatory requirements like OECD/ICH guidelines and Good Laboratory Practices to ensure quality. Acute, sub-acute, and chronic toxicity tests provide information on toxicity effects from single or repeated substance exposure over different time periods and help determine safe doses for clinical trials.
This document describes Barktastic natural apple berry treats for dogs. The treats contain concentrated fruit purees from apples and berries, as well as omega-3 and vitamin C. They are grain free and contain only natural ingredients like purified fish oil, calcium, and apple fiber powder. Nutrition facts are provided, listing the treats as low in calories, fat, and sugars, with fiber as the leading carbohydrate. The treats are presented as 100% natural, containing whole apples, and suitable for both training and occasional supplemental use.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise boosts blood flow, releases endorphins, and promotes changes in the brain which help enhance one's emotional well-being and mental clarity.
Fruit Snack Co. is opening a new fruit snack production facility in the vacant former CanGro Foods Inc. plant in St. Davids, Ontario. The facility will initially employ 9 people and process local fruits like peaches and pears into healthy, natural fruit snacks. The startup received $884,570 in funding from the province and will provide new markets for local fruit growers to sell bruised or damaged crops. The owner, John Boot, has over 20 years of experience in the dried fruit snack industry and previously founded and sold another successful fruit snack company in British Columbia.
Fruit Snack Co. is opening a new fruit snack production facility in the vacant former CanGro Foods Inc. plant in St. Davids, Ontario. The facility will initially employ 9 people and process local fruits like peaches and pears into healthy, natural fruit snacks. The startup received $884,570 in funding from the province and will provide new markets for local fruit growers to sell bruised or damaged crops. The owner, John Boot, has over 20 years of experience in the dried fruit snack industry and hopes to create a similar successful operation in Niagara to process local fruits into snacks.
This document is a nutrition label and packaging for Barktastic Fruit Treats, a natural dog treat made from apple and berries. The treats are intended to be healthy training rewards for dogs, containing vitamin C, omega-3 fatty acids, and no artificial flavors, colors, preservatives or added sugars. The story of Rosie, a shy puppy who was inspired to create the treats, is described on the packaging. Feeding guidelines recommend the treats as a supplemental snack equivalent to half an apple.
Fortis Clinical Research Ltd. is a leading clinical research organization in India that provides various clinical research services to support the global pharmaceutical industry in drug development. The document outlines Fortis' vision, services, leadership team, facilities, capabilities, and experience conducting various types of clinical trials and bioanalytical work.
Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics ( PDFDrive...InsSilva801685
This document provides a table of contents for the book "Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics". The table of contents lists 50 chapters organized into 6 parts that cover topics such as principles of laboratory medicine, analytical techniques and instrumentation, analytes, pathophysiology, molecular diagnostics, and reference information.
Dr. Manoj Kumar is a research scientist with a Ph.D. in Dairy Microbiology. He has over 4 years of research experience and 2.8 years of industrial experience as a Microbiologist. He is currently a Young Scientist at the National Institute of Nutrition in Hyderabad, India. His research focuses on developing recombinant probiotic bacteria to combat pathogens and metabolic disorders. He has received several awards and research grants for his work.
Biologics World Taiwan 2016 (email me at justin.dejesus@imapac.com) Justin Barin de Jesus
The ONLY biopharmaceutical
gathering in Taiwan
Emphasizes on new business collaborations, demonstrate state-of-the-art developments and to propel Taiwan's biotech firms onto the world stage.
Company Profile Kalgen Innolab Innobiogram_2022.pptxasmadiarrum
Kalgen Innolab is a Japanese-Indonesian clinical laboratory partnership established in 2016 to provide integrated healthcare services. It has over 1000 test parameters and processes 120,000-160,000 samples per day. The laboratory focuses on strengthening its position as a reference lab through expanding its test portfolio and nationwide sample collection network. It aims to support antimicrobial resistance control programs through providing Innobiogram reports with clinical microbiologist interpretation.
This investor presentation summarizes Pressure BioSciences' business and technology. PBI develops and sells instruments and consumables for sample preparation using its patented Pressure Cycling Technology platform. Key points include that PBI has over 275 PCT systems installed, has accomplished revenue growth and debt reduction in recent years, and signed a marketing agreement with SCIEX to co-promote its PCT-SWATH technology for mass spectrometry applications. The presentation outlines PBI's technology applications, market opportunities, customer base, and near-term growth drivers including the SCIEX partnership and new product releases.
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
Mallikarjuna G currently works as a research associate in pharmacokinetics at Quest Life Sciences Pvt Ltd in Chennai. He has over 5 years of experience in areas like feasibility studies, clinical trial protocol design, clinical report writing, sample processing, and subject monitoring. He holds an MPharmacy in Pharmacology and has experience in areas like in vitro pharmacokinetic studies, pharmacological screening models, and analytical techniques like chromatography. He is skilled in MS Office, has published 3 research papers and 2 review papers, and has participated in workshops and seminars in fields like experimental pharmacology and molecular biology.
This presentation by Pressure BioSciences discusses their Pressure Cycling Technology platform for biological sample preparation. Some key points:
- PCT uses ultra-high pressure to break up cell walls and extract biomolecules, achieving better results than mechanical methods.
- The market for biological sample preparation is multi-billion dollars. PCT addresses the need for improved sample prep methods.
- Over 275 PCT systems have been installed at over 150 customer sites. There are over 100 publications highlighting PCT's advantages.
- Recent accomplishments include a co-marketing agreement with SCIEX, a leader in analytical technologies, and sales of their new Barocycler 2320EXTREME system.
SMi Group's 7th annual Advances in Cell Based Assays conferenceDale Butler
This document summarizes a two-day conference on advances in cell-based assays being held on November 11-12, 2014 in London. The conference will explore the latest developments in cell-based assays and their application in drug discovery and development. Speakers will include representatives from pharmaceutical companies such as GSK, AstraZeneca, Novartis, UCB, and Merck Serono, as well as academics. Topics will include the use of cell-based assays in biologics drug discovery, challenges in validation and regulation, phenotypic screening, stem cell technologies, and 3D cell cultures. Workshops on leveraging cell-based assays for open innovation and evaluating cell-based assays in drug discovery will also be offered
Biopharma Production & Development Week 2015 Rita Barry
What’s New for 2015
- C-Level Panel: Cutting Edge Insights on China’s Growing Biotech Market
- China FDA Special Address
- 80+ Key Expert Speakers from Asia’s leading Pharma & Biotech
- 1 Joint Exhibition & Networking Area
- 4 Days of Expert Knowledge Sharing
- Revamped Program with New Special Focused Tracks & Sessions
The Solaris Wellness Analyzer is a diagnostic system that analyzes urine and saliva samples to provide a comprehensive overview of a patient's health. It tests over a dozen biomarkers and biomarkers and generates two reports - one with numeric results and one explaining treatment recommendations. The system was developed by Dr. David Baltimore and aims to allow doctors to efficiently screen multiple health indicators at once in their office. However, more empirical evidence is still needed to fully validate its clinical usefulness.
This document provides information about the second issue of the third volume of the International Journal of Scientific and Innovative Research (IJSIR), published in July-December 2017. The journal aims to promote multidisciplinary research across various fields. This issue contains 18 research papers covering different areas of science and technology. The Editor-in-Chief acknowledges the editorial committee and contributors for their work in publishing this issue of the journal.
The document discusses the drug development process from discovery to approval. It covers key stages including discovery research, preclinical testing, clinical trials, regulatory review and approval, and product launch. Key aspects addressed are screening compounds for drug candidates, assessing safety and efficacy in animal and human studies, developing formulations, and engaging regulatory agencies for approval to market a new drug. The overall goal is to discover, develop and launch new pharmaceutical products that treat diseases and conditions.
Chair of Finance and Investment Track at Bangalore India Bio 2011 : Kapil Kha...Kapil Khandelwal (KK)
This document contains the schedule for the BioAsia 2011 conference held on May 4-6, 2011 in Hyderabad, India. The schedule lists various panel discussions, presentations and keynote speeches on topics related to systems biology, regenerative medicine, clinical trials, bioinformatics, vaccines, diagnostics, drug discovery, finance, human resources, and agricultural and industrial biotechnology. It provides timing, chairs and speakers for each session. The conference included a CEO conclave, bio partnering platform, exhibition and poster presentations, and bio excellence awards.
Sitec Labs provides contract research services with the vision to be a global leader in the industry through innovation and quality excellence. Their mission is to support drug discovery and development, ensure compliance with quality standards, and be a long-term trusted partner. They have over 350 staff members across two facilities totaling 75,000 square feet. Services include analytical research, impurity synthesis, bioavailability/bioequivalence studies, and regulatory compliance.
This document discusses key concepts in pharmaceutics and drug development. It covers:
1. The branches of pharmaceutics including pharmacokinetics, pharmacodynamics, biopharmaceutics, and pharmaceutical technology.
2. The process of drug discovery and development, from identifying drug targets through preclinical and clinical testing.
3. The different phases of clinical trials and timelines for drug approval.
4. The definitions of key terms used in drug development like target, hit, lead, candidate, and product.
5. The differences between brand drugs, generics, and biosimilars.
This resume summarizes Sean Ekins' experience and qualifications. He has over 17 years of experience in drug discovery from large pharmaceutical companies to small biotechs. He is an expert in computational and in vitro tools for accelerating drug discovery and reducing compound attrition. He has held leadership roles at several companies and currently works as an independent consultant advising various organizations. He is also an active researcher and writer with over 200 publications.
This document describes the development of a new diagnostic method called ProteAl for the rapid detection of Proteus bacteria. 2-methylbutanal was identified as a volatile organic compound biomarker specifically produced by Proteus. A fluorescent assay was developed using the reagent 5-dimethylaminonaphthalene-1-sulfonylhydrazine to detect 2-methylbutanal. This ProteAl assay could identify Proteus within 7 hours of growth and differentiated it from other common uropathogens. The production of 2-methylbutanal by Proteus was found to be regulated by the isoleucine metabolic pathway. Rational design of growth medium with increased isoleucine enhanced the yield of
Similar to Nuliv An Overview Of Nu Liv Science 2010 6 21 (20)
2. NuLiv Operates on 6 Interconnected Business Platforms
1. Focused RESEARCH on METABOLISM (slides 3- 16)
2. Discovery of novel, safe, and BIOACTIVE botanical FRACTIONS &
COMPOUNDS (slides 17 - 25)
3. Development of PRODUCTION PROCESS for NuLiv’s proprietary
bioactive fractions and compounds (slides 26 – 28)
4. Development of safe and effective SUPPLEMENT products (slides
29)
5. SOURCING and QC of botanical ingredients (slides 30 – 31)
6. Futuristic WELLNESS products and services platform (A NuLiv
experimental model) (slides 32)
3. Focused Research on Metabolism
For close to a decade, NuLiv has centered its research around
metabolism, the biological functions that sustain life, at cellular
and systemic levels
1. Research initiatives (slides 4 – 6)
1.1 Central belief
1.2 Hypothesis
1.3 Strategy
2. Life Science and Clinical Research platforms (slides 7 –14)
2.1 Facility
2.2 Staff & advisors
2.3 Validation platform
2.4 Supporting framework
3. Patents (slide 15)
4. Papers (slide 16)
4. The Central Belief that laid down
the Foundation for Our Research
TCM offers the best organized and time tested holistic
and systemic health wisdom.
NuLiv’s research idea, discovery of novel bioactive
ingredients, and development of nutritional products
should germinate from this knowledge base
5. The Hypothesis Our Research Strategy is Built Upon
• “Qi” (breathing, life force, energy) and “Xue” (circulation),
the foundation of TCM principle, are the metaphysical
transformation and final manifestation and distribution
of nutrients in human body.
• The biological pathway of this manifestation and distribution,
i.e., nutrient absorption, transportation of nutrients through
bodily fluids (blood included), metabolic and catabolic
functions, regulation of haemopoiesis & angiogenic functions,
even its effect on immune functions, are all integral to this
final manifestation.
• “Qi” and “Xue” herbs must be bioactively involved in the
various biological pathways and functions. Study of these
herbs should offer better odds of novel discoveries and
understanding of their benefits toward human health.
.
6. Our Strategy is to Build a Research Platform that
Allow us to Discover Novel Bioactive Compounds
from Chinese “Qi” and “Xue” Herbs
1. Select safe and widely used TCM herbs as research subjects.
2. Extract, separate, fractionate, and purify these herbs to fraction
and/or compound levels.
3. Develop bioassays to identify purity and concentration level of
these fractions and compounds.
4. Formulate application specific functional ingredients composed
of these fractions and/or compounds and assay for their
efficacies.
5. Test ingredient efficacy and safety to the technical or financial
level that is feasible; cell, animal and human.
6. Develop and test for ingredient reproducibility and stability.
7. NuLiv’s Advanced and Integrated
Life Science and Clinical Research Platform
Component Description
Facility NuLiv Taipei Laboratory
NuLiv Shanghai Laboratory
Management, Staff and
Advisors
Highly educated and trained in business, multi
scientific & clinical disciplines, and work closely
in a truly interdisciplinary manner
Discovery and Validation In-house and 3rd
party in vitro, in vivo, and
human use study platforms
Supporting
Framework/Network
Supported by NuLiv’s own subsidiaries and
affiliates, and long term strategic partners and
alliances in many distinguished academic and
research institutions
8. Research Facilities
Taipei and Shanghai Laboratories
• NuLiv Taipei (NDMC) Laboratory
1. Research initiatives
2. Research: Chemistry, cell assay, animal and human study
on plant derived bioactive fractions/compounds
3. Product design and development
4. Production process development
• NuLiv Shanghai Laboratory
1. Extraction, fractionation, purification of botanicals
2. Production process, MOA, and CMC development
3. Sourcing and Procurement
4. QA and QC
11. NuLiv Management /Business & Research Executives
Founder & CEO
Austin Wang, M.S. NuLiv Holdings, Inc. (World Headquarters) Taipei City,
Taiwan
Executive Director
Y.H. Lee, M.D. Vice Chancellor, China Medical Univ. (Taiwan), Previously
Dean, Chang Kung Medical School, Dep. Director, Chang Kung Hospital
System (10,000+ beds)
Principle Scientific Advisor
H.C. Lin, Ph.D. Univ. of North Carolina. Taught TCM at NDMC for over 20
years. Pioneered the hypothesis that “Qi” herbs regulate absorption and
other metabolic functions
President
Americas, Europe, Asia, Africa
Business Development
Sales & Marketing Representative
Americas, Europe, Asia, Africa
Michael Wang, M.S. NuLiv Science USA, Walnut, CA
David Allen, Ph.D. World Wellness, LLC., San Diego, CA
President
Greater China
David Wu, Ph.D. Business Administration, Univ. of South Australia,
Director
Research & Development
NuLiv Taipei Laboratory
Thomas Yang, Ph.D., Molecular Microbiology, Univ. of Texas, Southwestern
Medical Center
Director
NuLiv Shanghai Laboratory
Sunnie Sun, Ph.D., Pharm. Analysis, Sheng Yang Pharm. Univ.
Director
Clinical Research
Rose Chen, M.D., Ph.D., Shanghai TCM University
12. NuLiv’s Scientific Advisors
Chang, T.C., Ph.D. Biochemistry, Univ. of Illinois, Professor, Dept. of Biochemistry, National Defense
Medical Center,Taiwan
Chang, W.L., Ph.D. Pharmacy, National Taiwan Univ., Professor, School. of Pharmacy, National Defense
Medical Center, Taiwan
Kuo, C.H., Ph.D. Physiokinetics, Univ. of Texas, Professor and Chair, Department of Exercise Science,
National Taipei Physical Education College, Taiwan
Chen, C.X., Professor Director, Department of Pharmacology, TCM Univ., Shanghai, China.
Serves as our toxicity and safety advisor on TCM and other herbs
Komatsu, Yasuhiro,
Ph.D.
Medical science, Juntendo University, Prior Dean of R&D department, Tsumura &
Co.
Chu, C. H, Ph.D. Food engineering, University of Tokyo, expert in pre-clinical pharmacology tests
Fan, David, Ph.D. Senior Lecturer, Trinity College, Cambridge Univ., Editor-in-chief, Angiogenesis
Hsieh, Steve, Ph.D. Nutritional Biochemistry, Univ. of Wisconsin, Ex Vice Chairman, National Science
Council, R.O.C. Government
Looi Hwang, Ph.D. Industrial & Environmental Pharmacy Ph.D. from Purdue, previously G.M. of MSD,
Hanzhou, China & and Merck of Singapore
J.K. Luo, Ph.D. Editor (acting), Journal of Heterocyclic Chemistry, Professor at University of S.
Florida
Funfack, Wolf, M.D. Metabolic Balance founder.
Peng, C.K., Ph.D. Statistical Physics, Boston Univ., Assoc. Professor/Co-director, Rey Institute for
Nonlinear Dynamics in Physiology and Medicine, Harvard Medical School.
13. Our In vitro, In vivo, and
Human Research Platforms
In vitro Assay
Systems
• Establish any cell assay system in 2 to 4 months
• Currently available cell assay systems: HaCaT and HDF cell,
Caco-2, 3T3-L1, HSMMT,HepG2, HCH & SW 1353, and etc
In vivo Assay for
efficacy and
safety Systems
• Nude mice for cancer and cosmetic studies
• db/db mice for diabetes and wound healing studies
• SD rat for ergogenic and diabetes studies
• absorption model (portal vein)
• Acute and Sub-acute Toxicity
Human use
Study
• Topical skin care test
• Ergogenic test
• Cancer adjuvant therapy
14. Our Supporting Framework & Network
Facility, equipment,
interdisciplinary consultation
National Defense Medical Center
Industrial Technology Research institute,
Taiwan
Yang Ming University, Taiwan
Taipei Medical University, Taiwan
In vivo and human study China Pharmaceutical University, Nanjing,
China Taipei Physical Education College
I-Shou University Hospital
NuLiv Wellness Clinic
Consultation, Cellular science
Metabolic health
TCM pharmacology &
toxicology
angiogenesis
Yang Ming Univ. Stem Cell Research Center
Taipei Medical Univ. Stem Cell Research Center
Dr. Wolfgang Funfack, Metabolic Balance, De.
Shanghai TCM university
China Medical University, Taiwan
Trinity college, Cambridge University, UK
15. Title Country/Region Patent NO. Application NO.
Method for Regulating Nutrient
Absorption with Astragalosides
USA US11/426,029
China CN200610090113.0
Taiwan I271195
Method for Regulating Nutrient
Absorption with Ginsenosides
USA US11/426,06
China
CN200610090114.5
CN200910178493.7
CN200910178492.2
Taiwan I317280
Method for Skin Care PCT PCT/US07/77326
USA US11/469,659
China CN200710089586.3
Taiwan TW095132614
Use of Cycloartane compounds for
treating arthritis
USA US12/353,779
China N/A yet
Taiwan TW098135306
Patents from NuLiv’s Research
16. • Effect of ginsenosides on glucose uptake in human Caco-2 cells is mediated through altered Na+/glucose cotransporter 1 expression.
Chang TC, Huang SF, Yang TC, Chan FN, Lin HC, Chang WL. J Agric Food Chem. 2007 ;55(5):1993-8.
• Effect and mechanism of ginsenosides CK and Rg1 on stimulation of glucose uptake in 3T3-L1 adipocytes. Huang YC, Lin CY,
Huang SF, Lin HC, Chang WL, Chang TC. J Agric Food Chem. 2010 ;58(10):6039-47.
• Glycogen overload by postexercise insulin administration abolished the exercise-induced increase in GLUT4 protein. Chou CH,
Tsai YL, Hou CW, Lee HH, Chang WH, Lin TW, Hsu TH, Huang YJ, Kuo CH. J Biomed Sci. 2005 ;12(6):991-8.
• The induction of orphan nuclear receptor Nur77 expression by n-butylenephthalide as pharmaceuticals on hepatocellular
carcinoma cell therapy. Chen YL, Jian MH, Lin CC, Kang JC, Chen SP, Lin PC, Hung PJ, Chen JR, Chang WL, Lin SZ, Harn HJ.Mol
Pharmacol. 2008 ;74(4):1046-58.
• The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and
in vivo. Tsai NM, Chen YL, Lee CC, Lin PC, Cheng YL, Chang WL, Lin SZ, Harn HJ. J Neurochem. 2006;99(4):1251-62.
• The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Tsai NM, Lin SZ, Lee CC, Chen SP, Su HC,
Chang WL, Harn HJ. Clin Cancer Res. 2005;11(9):3475-84.
• Acetone extract of Angelica sinensis inhibits proliferation of human cancer cells via inducing cell cycle arrest and apoptosis. Cheng
YL, Chang WL, Lee SC, Liu YG, Chen CJ, Lin SZ, Tsai NM, Yu DS, Yen CY, Harn HJ. Life Sci. 2004;75(13):1579-94.
• Ginsenoside Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor
through the oestrogen beta receptor.
• Leung KW, Cheung LW, Pon YL, Wong RN, Mak NK, Fan TP, Au SC, Tombran-Tink J, Wong AS. Br J Pharmacol. 2007;152(2):207-15.
• Metabolites of ginsenosides as novel BCRP inhibitors. Jin J, Shahi S, Kang HK, van Veen HW, Fan TP. Biochem Biophys Res
Commun. 2006;345(4):1308-14.
• Signaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells. Leung KW, Cheng YK, Mak NK, Chan
KK, Fan TP, Wong RN.FEBS Lett. 2006 ;580(13):3211-6
• Modulating angiogenesis: the yin and the yang in ginseng. Sengupta S, Toh SA, Sellers LA, Skepper JN, Koolwijk P, Leung HW,
Yeung HW, Wong RN, Sasisekharan R, Fan TP. Circulation. 2004;110(10):1219-25.
• S.-F. Huang, Y.-C. Huang, J.-Y. Lin, W.-L. Chang and T.-C. Chang (2010) Effect of Ginsenoside Rb1 on Glucose Uptake and Expression
of Glucose Transporters in Animal Cells, Adaptation Biology and Medicine, Volume 6: Cell Adaptations and Challenges, 2010 (In
Press).
• Yu-Chuan Huang, Cheng-Yu Lin, Su-Fen Huang, Wen-Liang Chang, and Tsu-Chung Chang (2010) Differential effect of oleanolic and
ursolic acid on GLUT4 expression and membrane translocation in 3T3-L1 adipocytes, Manuscript in preparation.
Published Papers and papers in Press
17. Discovery of Novel, Safe, and Bioactive
Botanical Fractions and Compounds
After a decade of following our research central belief, hypothesis, and strategy,
and by subjecting dozen “Qi” and “Xue” herbs through our in vitro, in vivo, and
human studies, we have discovered 6 bioactive fractions and compounds in
these herbs that have shown dose-dependent benefit toward specific human
functions
1. 6 bioactive fractions / compounds discovered (slide 18)
2. Functional ingredients formulated with our bioactive fractions/compounds
2.1 Brief descriptions of the 6 functional ingredients (slide 19)
2.2 ActiGinTM
, for optimum exercise energy, endurance, and recovery (slide 20)
2.3 AstraGinTM
, for enhanced nutrients absorption at the cellular level (slide 21)
2,4 AstrionTM
, for youthful and radiant skin (slide 22)
2.5 ImmunoAGTM
, for adjuvant therapy (slide 23)
2.6 OsteoSineTM
, for reversing bone loss (slide 24)
2.7 Slim&FitTM
, for weight control and metabolic syndrome (slide 25)
18. 6 Fractions / Compounds from our
Research and Their Biological Functions
Fractions/Compounds Discovered Functions
NL-F001 Anti-angiogeneis
NL-F002 Enhance amino acids, vitamins, and
glucose absorption at the cellular level;
anti-angiogenesis
NL-F003 Increase Adiponectin secretion
Ergogenic/recovery
NL-F004 Enhance amino acids, vitamins, and
glucose absorption at the cellular level
NL-F006 Enhance amino acids, vitamins, and
glucose absorption at the cellular level ;
Increase Adiponectin secretion
NL-F007 Increase collagen and hyaluronic acid
secretion; decrease MMP-1 secretion
19. Proprietary Nutraceutical Ingredients Formulated with
NuLiv Bioactive Fractions and Compounds
AstraGinTM
An all natural nutrient uptake enhancing complex that improves amino acids, glucose,
vitamins absorption by 62%, 57%, 50% through regulation and parallel alteration on both
the protein and mRNA expression levels of the nutrient transporter genes
AstrionTM
Reduces the number and appearance of fine lines & wrinkles, skin discoloration due to
sun damage, and firms, tones, and hydrates skin through increased dermal genesis and
UV protection. Dermal genesis promotes the synthesis of new collagen and hyaluronic
acid and, at the same time, reduces the breakdown of existing collagen due to UV light
destruction
ActiGinTM
Increased delivery of glucose to muscle cells; Protect against free radical attack after
exercise; Anti-inflammation; Minimize muscle cell damage; Increased glycogen
replenishment after Intensive workout
ImmunoAGTM
ImmunoAGTM
promotes nutrient absorption and metabolism in intestinal cells, Inhibits
abnormal cell proliferation and angiogenesis, induces abnormal cell mitotic arrest and
apoptosis through the activation of multiple signal pathways. In an in vivo study,
ImmunoAGTM
demonstrated to inhibit abnormal cell growth by 44% and prolonged the
life of subcutaneous abnormal cell bearing rats by 33% when compared to a control
group.
OsteoSineTM
Promotes bone mineral density and structural strength by enhancing bone formation
and reducing bone resorption. This dual action has been confirmed by NuLiv’s PO (post-
ovariectomized) female rats (equivalent to menopausal women) and RA (retinoic Acid-
induced acute osteoporosis) rats (Equivalent to none gender or age-related osteoporosis
persons) models.
Slim&FitTM Decreases the intestinal absorption of glucose through the regulation and parallel
alteration on both the protein and mRNA expression levels of the nutrient transporter
genes while increases the glucose absorption in muscle and adipocyte cells through
insulin independent pathway.
24. OsteoSineTM
In vivo Study
Normal bone treated with retinoic
acid to simulate osteoporosis
conditions
Treated with 400 mg of
OsteoSine daily for 5 weeks
26. Development of Production Process
for
NuLiv’s Proprietary Bioactive Fractions and Compounds
We develop production process, reference standard, MOA,
bioassay, and QA Programs for the production of our
proprietary active fractions and compounds so that they
have the same purity and concentration level as in those
used in our research.
1. Extraction, Fractionation, Separation, and Purification of
Raw Herbs to the Fraction and Compound Levels (slide
27)
2. Purity and concentration level of our proprietary
bioactive fractions / compounds are identified and
measured by specific bioassays (slide 28)
28. The Purity and Concentration Level of our Bioactive Fractions
and Compounds are Identified and Measured by Specific Bioassays
Active constituentsMedicinal
plants
Crude
extracts
Fraction 1
Fraction 2
Fraction 3
Fraction 4
Fraction 5
Fraction 6
…
fractionationextraction
Formulation
Depend on function
Products & Marketing
Structure
elucidation
UV
MS
NMR
IR
CD
1
H NMR
13
C NMR
2D NMR
separation
Absorption
Anti-cancer
Skin care, etc
Active
constituents
QC systems
-LC/UV
-GC/MS
Bioassay
QC
29. Our Supplements are Highly Effective and Safe
in Supporting Critical Human Health Functions
30. Our Sourcing Operations Guarantees Premier Quality Products with
Competitive Prices and Timely Delivery to our Customers
NuLiv/Customer specifications/requirements
Vendor
Vendor Survey for Certificates, Qualifications, MOA, COA, sample
Onsite Vendor Survey
Disqualified
Qualified
Contract/Agreement
Primary
suppliers
Secondary
Supplier
31. Our Quality Control on Sourcing Operations
Closely Follows Pharmaceutical Protocols
• Follow USP/NF, AOAC, ChP, GB, In-house developed MOA
• PhytoMonitorTM
Double QC Checking
– First tested at the manufacturing sites or production sample tested at
NuLiv shanghai Laboratory
– Production order samples tested at NuLiv Shanghai laboratory before
order can be shipped.
– Samples can be tested by independent 3rd party laboratories in the U.S.
for additional quality control.
– Alkemists Pharmaceuticals, CA
– Michelson Lab, CA
– Oregon Department of Agriculture (heavy metals)
32. Futuristic Wellness Product and Service Platform
(A NuLiv Experimental Model)
Wellness Advisors
Interactive and personal
wellness information exchange
and virtual community management
NuLiv Wellness Management Inc.
Device
HRM Meridian
Blood analysis
CD/Biochips
Nutritional Sciences
NuLiv Laboratories
(Slides 1 – 42)
System complexity analysis
DynaDx – Harvard Reylab
Evidence based wellness
know-how
NuLiv Wellness Clinic
Wellness/Sub-clinical Primary Care Clinic
Cellular sciences
Steminent Therapeutic Inc.
33. Whether its research capability,
cutting edge proprietary botanical fractions,
highly effective nutritional supplement products,
premium quality botanical ingredients,
or even Futuristic Wellness Model,
NuLiv Science is the company that you can trust.
Thank you